Search results
Results from the WOW.Com Content Network
(Reuters) -AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low ...
AstraZeneca said Imfinzi was also recently granted Breakthrough Therapy Designation by the FDA in the same setting, which will help accelerate the regulatory review. Small cell lung cancer is a ...
AstraZeneca has long been in the oncology and other disease spaces, but rose to popularity in recent years with the success of its COVID-19 vaccine.The company has since withdrawn the vaccine due ...
In 2019 AstraZeneca agreed to pay up to US$6.9 billion to jointly develop DS-8201 with Japan's Daiichi Sankyo. It is intended to replace Herceptin for treating breast cancer. DS8201 carries eight payloads, compared to the usual four. [2]
Vandetanib, sold under the brand name Caprelsa, is an anti-cancer medication that is used for the treatment of certain tumours of the thyroid gland.It acts as a kinase inhibitor of a number of cell receptors, mainly the vascular endothelial growth factor receptor, the epidermal growth factor receptor, and the RET-tyrosine kinase.
Endocrine-Related Cancer was founded as Reviews on Endocrine-Related Cancer, the in-house journal of Zeneca (now AstraZeneca) published by its parent company ICI Pharmaceuticals. It was taken over by the Society for Endocrinology in 1994 when it was renamed, and the remit was extended to include a limited number of original research articles to ...
(Reuters) -A combination of AstraZeneca's blockbuster cancer drug Tagrisso, with chemotherapy to treat a type of lung cancer, has been accepted and granted priority review by the U.S. Food and ...
The US Food and Drug Administration (FDA) granted the application for moxetumomab pasudotox fast track, priority review, and orphan drug designations. [4] [17] The FDA granted the approval of a Biologics License Application for Lumoxiti to AstraZeneca Pharmaceuticals. [4] This was subsequently transferred to Innate Pharma in March 2020. [18]